| First Author | Boutet M | Year | 2025 |
| Journal | Immunity | Volume | 58 |
| Issue | 8 | Pages | 2035-2053.e9 |
| PubMed ID | 40749665 | Mgi Jnum | J:371963 |
| Mgi Id | MGI:8238814 | Doi | 10.1016/j.immuni.2025.07.008 |
| Citation | Boutet M, et al. (2025) Mutations in MLL3 promote breast cancer progression via HIF1alpha-dependent intratumoral recruitment and differentiation of regulatory T cells. Immunity 58(8):2035-2053.e9 |
| abstractText | Loss-of-function mutations in MLL3, encoding the histone methyltransferase MLL3/KMT2C, are frequent in various cancer types. To examine the mechanisms whereby MLL3 suppresses tumorigenesis, we developed a mouse mammary-stem-cell-based tumor model bearing cancer-driver mutations, including loss of MLL3/KMT2C and p53 and constitutive phosphatidylinositol 3-kinase (PI3K) activation, recapitulating a genetic makeup of aggressive human breast cancers. MLL3 loss stabilized the transcription factor HIF1alpha, which increased secretion of the chemokine CCL2 by tumor cells and promoted recruitment of CCR2(+) regulatory T (Treg) cells. Treg cell depletion slowed tumor onset and progression. In human breast tumors, infiltration of Treg cells correlated with the presence of MLL3 mutations. HIF1alpha enforced BLIMP-1-dependent differentiation of tumor-infiltrating Treg cells into ICOS(hi)GITR(hi) effectors that secreted the immunosuppressive cytokines transforming growth factor beta (TGF-beta) and interleukin-10 (IL-10). Antibody targeting of ICOS or GITR depleted tumor Treg cells and inhibited tumorigenesis. Thus, MLL3 mutations shape an immunosuppressive tumor immune microenvironment in aggressive breast cancers and likely in other cancers where functional MLL3 is lost. |
